For instance, the elevated expression of Oncostatin M (OSM), a group of pleiotropic cytokines, has been associated with a poor response to TNFα blockers in certain patients with IBD, suggesting its potential as both a biomarker and a therapeutic target [24]. Here, OSM is linked to inflammatory bowel disease.